Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study assessed the effects of a single intravenous dose of secukinumab (AIN457) 10 mg/kg or canakinumab (ACZ885) 10 mg/kg on the signs and symptoms of dry eye. In addition, the pharmacokinetic, pharmacodynamic, and safety profiles of secukinumab and canakinumab were assessed. Blood samples were collected for the analysis of the effect of secukinumab and canakinumab on select biomarkers.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Secukinumab 10 mg/kg | Experimental | Patients received a single dose of secukinumab 10 mg/kg infused intravenously over a 2 hour period. |
|
| Canakinumab 10 mg/kg | Experimental | Patients received a single dose of canakinumab 10 mg/kg infused intravenously over a 2 hour period. |
|
| Placebo | Placebo Comparator | Patients received a single placebo infusion intravenously over a 2 hour period. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Secukinumab 10 mg/kg | Biological | Secukinumab was prepared in a sterile water solution. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline on the National Eye Institute Corneal Staining Scale (NEI-CSS) at Week 4 | Corneal staining was done with 2% sodium fluorescein instilled into the lower palpebral conjunctiva of each eye. Staining was assessed in 5 zones of the cornea (central plus 4 quadrants) and rated on a scale of 0 (no staining) to 3 (severe, confluent staining). A mean of the 5 zones for the study eye was calculated. A higher score indicates a drier eye. A negative change score indicates improvement in dryness. | Baseline to Week 4 |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline on the Ora Corneal Staining Scale at Weeks 1, 4, and 8 | Corneal staining was done with 2% sodium fluorescein instilled into the lower palpebral conjunctiva of the study eye. Staining was assessed in 3 regions (inferior, superior, and central) of the cornea and rated on a scale of 0 (no staining) to 4 (confluent staining). A mean of the 3 zones was calculated. A higher score indicates a drier eye. A negative change score indicates improvement in dryness. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ora Inc, 300 Brickstone Square, | Andover | Massachusetts | 01810 | United States |
One patient randomized to the secukinumab group did not receive study drug and was not included in any of the analysis sets.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Secukinumab 10 mg/kg | Patients received a single dose of secukinumab 10 mg/kg infused intravenously over a 2 hour period. |
| FG001 | Canakinumab 10 mg/kg | Patients received a single dose of canakinumab 10 mg/kg infused intravenously over a 2 hour period. |
| FG002 | Placebo | Patients received a single placebo infusion intravenously over a 2 hour period. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Secukinumab 10 mg/kg | Patients received a single dose of secukinumab 10 mg/kg infused intravenously over a 2 hour period. |
| BG001 | Canakinumab 10 mg/kg | Patients received a single dose of canakinumab 10 mg/kg infused intravenously over a 2 hour period. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age Continuous | One patient randomized to the secukinumab group did not receive study drug and was not included in the analysis of demographic data. |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline on the National Eye Institute Corneal Staining Scale (NEI-CSS) at Week 4 | Corneal staining was done with 2% sodium fluorescein instilled into the lower palpebral conjunctiva of each eye. Staining was assessed in 5 zones of the cornea (central plus 4 quadrants) and rated on a scale of 0 (no staining) to 3 (severe, confluent staining). A mean of the 5 zones for the study eye was calculated. A higher score indicates a drier eye. A negative change score indicates improvement in dryness. | All patient population: All randomized patients that received 1 full dose of a study drug per protocol. Two patients were not included in the all patient population (1 in each drug group) as they were not dosed per protocol or they did not receive the full dose of the assigned treatment. | Posted | Mean | Standard Deviation | Units on a scale | Baseline to Week 4 |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Secukinumab 10 mg/kg | Patients received a single dose of secukinumab 10 mg/kg infused intravenously over a 2 hour period. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Acute diverticulitis | Infections and infestations | MedDRA (14.0) | Non-systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Diarrhoea | Gastrointestinal disorders | MedDRA (14.0) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Study Director | Novartis Pharmaceuticals | 862 778-8300 |
Not provided
| ID | Term |
|---|---|
| D015352 | Dry Eye Syndromes |
| ID | Term |
|---|---|
| D007766 | Lacrimal Apparatus Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C555450 | secukinumab |
| C541220 | canakinumab |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Canakinumab 10 mg/kg | Biological | Canakinumab was prepared in a sterile water solution. |
|
|
| Placebo | Biological | The placebo solution for infusion contained 5% glucose. |
|
| Baseline to Weeks 1, 4, and 8 |
| Change From Baseline on the Schirmer Test at Weeks 1, 4, and 8 | The Schirmer test measures the production of tears. A small strip of filter paper is placed inside the lower eyelid (conjunctival sac) of each eye and the eyes are kept closed for 5 minutes. The paper is removed and the length of paper that is wet is measured as an index of tear production. The amount of tear production in the study eye was ranked on a 4 point scale: 0=Normal (≥ 15 mm wetting of the paper), 1=Mild (14-9 mm wetting of the paper), 2=Moderate (8-4 mm wetting of the paper), and 3=Severe (< 4 mm wetting of the paper). A higher score indicates a drier eye. A negative change score indicates improvement in dryness. | Baseline to Weeks 1, 4, and 8 |
| Change From Baseline in Tear Film Breakup Time at Weeks 1, 4, and 8 | Tear film breakup time was defined as the time of last blink to the appearance of the first growing micelle after instilling 5 μl of non-preserved 2% sodium fluorescein into the lower palpebral conjunctiva of the study eye. Measurement was repeated 3 times and a mean tear film breakup time calculated. A lower score indicates a drier eye. A positive change score indicates improvement in dryness. | Baseline to Weeks 1, 4, and 8 |
| Change From Baseline on the Conjunctival Redness Scale (Ora) at Weeks 1, 4, and 8 | Conjunctival redness was measured in the study eye at each visit by a masked evaluator. The evaluator compared the patient's study eye with a set of 5 reference photos showing a normal eye and eyes with various degrees of redness. Redness was scored on a scale of 0-5 with a white normal eye = 0 and an eye with the most redness = 5. A higher score indicates more redness. A negative change score indicates improvement in redness. | Baseline to Weeks 1, 4, and 8 |
| Change From Baseline in the Ocular Surface Disease Index (OSDI) at Weeks 1, 4, and 8 | The OSDI is an instrument for measuring dry eye disease severity and effect on vision-related functions. Patients were asked a series of 12 questions; patients responded to the questions in regard to both eyes. Responses ranged from 0=None of the time to 4=All of the time. OSDI was calculated as the sum of the 12 question scores x 25/number of questions answered. The total score ranged from 0-100. A higher score indicates drier eyes. A negative change score indicates improvement in dryness. | Baseline to Weeks 1, 4, and 8 |
| Desire for Artificial Tear Use at Day 1 and Weeks 1, 4, and 8 | Patients were instructed to record each occurrence of a desire for topical lubricant use in a patient diary. The percentage of patients in each of 6 categories (0-5, 6-10, 11-15, 16-20, 21-25, > 25 times) indicating the number of times a patient records a desire for artificial tear use per day was calculated at each time point. The percentage was calculated using the number of patients with any reported data on that day in the respective treatment group as the denominator. | Day 1 and Weeks 1, 4, and 8 |
| Change From Baseline in Best Corrected Visual Acuity at Weeks 1, 4, and 8 | Best corrected visual acuity (BCVA) was assessed in the study eye. BCVA measurements were taken in a standing position using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts at an initial testing distance specific to the test charts. The BCVA score is the number of letters read correctly by the patient. A decrease in the BCVA score indicates a worsening of vision. A positive change score indicates improvement. | Baseline to Weeks 1, 4, and 8 |
| BG002 | Placebo | Patients received a single placebo infusion intravenously over a 2 hour period. |
| BG003 | Total | Total of all reporting groups |
| Mean |
| Standard Deviation |
| years |
|
| Sex: Female, Male | One patient randomized to the secukinumab group did not receive study drug and was not included in the analysis of demographic data. | Count of Participants | Participants |
|
Patients received a single dose of secukinumab 10 mg/kg infused intravenously over a 2 hour period.
| OG001 | Canakinumab 10 mg/kg | Patients received a single dose of canakinumab 10 mg/kg infused intravenously over a 2 hour period. |
| OG002 | Placebo | Patients received a single placebo infusion intravenously over a 2 hour period. |
|
|
| Secondary | Change From Baseline on the Ora Corneal Staining Scale at Weeks 1, 4, and 8 | Corneal staining was done with 2% sodium fluorescein instilled into the lower palpebral conjunctiva of the study eye. Staining was assessed in 3 regions (inferior, superior, and central) of the cornea and rated on a scale of 0 (no staining) to 4 (confluent staining). A mean of the 3 zones was calculated. A higher score indicates a drier eye. A negative change score indicates improvement in dryness. | All patient population: All randomized patients that received 1 full dose of a study drug per protocol. Two patients were not included in the all patient population (1 in each drug group) as they were not dosed per protocol or they did not receive the full dose of the assigned treatment. | Posted | Mean | Standard Deviation | Units on a scale | Baseline to Weeks 1, 4, and 8 |
|
|
|
| Secondary | Change From Baseline on the Schirmer Test at Weeks 1, 4, and 8 | The Schirmer test measures the production of tears. A small strip of filter paper is placed inside the lower eyelid (conjunctival sac) of each eye and the eyes are kept closed for 5 minutes. The paper is removed and the length of paper that is wet is measured as an index of tear production. The amount of tear production in the study eye was ranked on a 4 point scale: 0=Normal (≥ 15 mm wetting of the paper), 1=Mild (14-9 mm wetting of the paper), 2=Moderate (8-4 mm wetting of the paper), and 3=Severe (< 4 mm wetting of the paper). A higher score indicates a drier eye. A negative change score indicates improvement in dryness. | All patient population: All randomized patients that received 1 full dose of a study drug per protocol. Two patients were not included in the all patient population (1 in each drug group) as they were not dosed per protocol or they did not receive the full dose of the assigned treatment. | Posted | Mean | Full Range | Units on a scale | Baseline to Weeks 1, 4, and 8 |
|
|
|
| Secondary | Change From Baseline in Tear Film Breakup Time at Weeks 1, 4, and 8 | Tear film breakup time was defined as the time of last blink to the appearance of the first growing micelle after instilling 5 μl of non-preserved 2% sodium fluorescein into the lower palpebral conjunctiva of the study eye. Measurement was repeated 3 times and a mean tear film breakup time calculated. A lower score indicates a drier eye. A positive change score indicates improvement in dryness. | All patient population: All randomized patients that received 1 full dose of a study drug per protocol. Two patients were not included in the all patient population (1 in each drug group) as they were not dosed per protocol or they did not receive the full dose of the assigned treatment. | Posted | Mean | Full Range | Seconds | Baseline to Weeks 1, 4, and 8 |
|
|
|
| Secondary | Change From Baseline on the Conjunctival Redness Scale (Ora) at Weeks 1, 4, and 8 | Conjunctival redness was measured in the study eye at each visit by a masked evaluator. The evaluator compared the patient's study eye with a set of 5 reference photos showing a normal eye and eyes with various degrees of redness. Redness was scored on a scale of 0-5 with a white normal eye = 0 and an eye with the most redness = 5. A higher score indicates more redness. A negative change score indicates improvement in redness. | All patient population: All randomized patients that received 1 full dose of a study drug per protocol. Two patients were not included in the all patient population (1 in each drug group) as they were not dosed per protocol or they did not receive the full dose of the assigned treatment. | Posted | Mean | Full Range | Units on a scale | Baseline to Weeks 1, 4, and 8 |
|
|
|
| Secondary | Change From Baseline in the Ocular Surface Disease Index (OSDI) at Weeks 1, 4, and 8 | The OSDI is an instrument for measuring dry eye disease severity and effect on vision-related functions. Patients were asked a series of 12 questions; patients responded to the questions in regard to both eyes. Responses ranged from 0=None of the time to 4=All of the time. OSDI was calculated as the sum of the 12 question scores x 25/number of questions answered. The total score ranged from 0-100. A higher score indicates drier eyes. A negative change score indicates improvement in dryness. | All patient population: All randomized patients that received 1 full dose of a study drug per protocol. Two patients were not included in the all patient population (1 in each drug group) as they were not dosed per protocol or they did not receive the full dose of the assigned treatment. | Posted | Mean | Full Range | Units on a scale | Baseline to Weeks 1, 4, and 8 |
|
|
|
| Secondary | Desire for Artificial Tear Use at Day 1 and Weeks 1, 4, and 8 | Patients were instructed to record each occurrence of a desire for topical lubricant use in a patient diary. The percentage of patients in each of 6 categories (0-5, 6-10, 11-15, 16-20, 21-25, > 25 times) indicating the number of times a patient records a desire for artificial tear use per day was calculated at each time point. The percentage was calculated using the number of patients with any reported data on that day in the respective treatment group as the denominator. | All patient population: All randomized patients that received 1 full dose of a study drug per protocol. Two patients were not included in the all patient population (1 in each drug group) as they were not dosed per protocol or they did not receive the full dose of the assigned treatment. | Posted | Number | Percentage of patients | Day 1 and Weeks 1, 4, and 8 |
|
|
|
| Secondary | Change From Baseline in Best Corrected Visual Acuity at Weeks 1, 4, and 8 | Best corrected visual acuity (BCVA) was assessed in the study eye. BCVA measurements were taken in a standing position using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts at an initial testing distance specific to the test charts. The BCVA score is the number of letters read correctly by the patient. A decrease in the BCVA score indicates a worsening of vision. A positive change score indicates improvement. | All patient population: All randomized patients that received 1 full dose of a study drug per protocol. Two patients were not included in the all patient population (1 in each drug group) as they were not dosed per protocol or they did not receive the full dose of the assigned treatment. | Posted | Mean | Standard Deviation | Units on a scale | Baseline to Weeks 1, 4, and 8 |
|
|
|
| 1 |
| 26 |
| 3 |
| 26 |
| EG001 | Canakinumab 10 mg/kg | Patients received a single dose of canakinumab 10 mg/kg infused intravenously over a 2 hour period. | 0 | 22 | 8 | 22 |
| EG002 | Placebo | Patients received a single placebo infusion intravenously over a 2 hour period. | 0 | 24 | 4 | 24 |
| Nasopharyngitis | Infections and infestations | MedDRA (14.0) | Systematic Assessment |
|
| White blood cell count decreased | Investigations | MedDRA (14.0) | Systematic Assessment |
|
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA (14.0) | Systematic Assessment |
|
The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.
|
| Week 8 |
|
|
| Week 8 |
|
|
| Week 8 |
|
|
| Week 8 |
|
|
| Week 8 |
|
|
| Day 1, 11-15 times |
|
| Day 1, 16-20 times |
|
| Day 1, 21-25 times |
|
| Day 1, > 25 times |
|
| Week 1, 0-5 times (n=24, 21, 24) |
|
| Week 1, 6-10 times |
|
| Week 1, 11-15 times |
|
| Week 1, 16-20 times |
|
| Week 1, 21-25 times |
|
| Week 1, > 25 times |
|
| Week 4, 0-5 times (n=24, 21, 24) |
|
| Week 4, 6-10 times |
|
| Week 4, 11-15 times |
|
| Week 4, 16-20 times |
|
| Week 4, 21-25 times |
|
| Week 4, > 25 times |
|
| Week 8, 0-5 times (n=16, 15, 13) |
|
| Week 8, 6-10 times |
|
| Week 8, 11-15 times |
|
| Week 8, 16-20 times |
|
| Week 8, 21-25 times |
|
| Week 8, > 25 times |
|
|
| Week 8 |
|